title: [A case of malignant gastric outlet stenosis palliated with self-expandable metallic stent and responding to TS-1, an oral fluorouracil derivative].
abstract: We report a case of advanced gastric cancer with antral stenosis that responded to an oral anticancer agent, TS-1, after metallic stent insertion. A 59 year-old man was admitted to our hospital because of abdominal distension and vomiting after meals. The diagnosis was advanced gastric cancer with antral stenosis and multiple liver metastases. FP therapy (CDDP 80 mg/m2 day 1 div, 5-FU 700 mg/m2 day 1-5 continuous div) was administered. Although endoscopic findings showed improvement after the first course, the condition of the patient did not improve. We therefore inserted a self-expandable metallic stent into the antral stenosis. After implantation, the patient was able to have regular meals, leave the hospital and return to work. TS-1 (120 mg daily), an oral fluorouracil derivative, was administered in the outpatient setting. A partial response (PR) was obtained after 2 courses with regression of multiple liver metastases and the primary tumor.
authors.affiliation: Dept. of Internal Medicine, Hamanomachi General Hospital.
authors.forename: Youichiro
authors.initials: Y
authors.lastname: Tokumitsu
authors.forename: Chikage
authors.initials: C
authors.lastname: Nagano
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsuura
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Seo
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsugi
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D004338:Drug Combinations; D017219:Gastric Outlet Obstruction / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D015607:Stents; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid